Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 3,019 matching trials from the live ClinicalTrials.gov search.
Conditions
HPV-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Hypopharynx
Interventions
Cisplatin, Radiation therapy, Vorinostat
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Solid Tumors, Thyroid Cancer, Soft-tissue Sarcoma, Cholangiocarcinoma
Interventions
Pazopanib, GSK1120212
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Conditions
Head and Neck Cancer
Interventions
Head and Neck Educational Handbook
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Phase 2 Interventional Results available

CHFR Methylation Status Esophageal Cancer Study

NCT01372202
Conditions
Esophageal Cancer
Interventions
Paclitaxel, Cisplatin, Oxaliplatin, 5-Fluorouracil, Radiotherapy, Esophagectomy
Drug · Radiation · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Head and Neck Cancer
Interventions
DNA stability analysis, microsatellite instability analysis, mutation analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years to 120 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
4
States / cities
Baltimore, Maryland • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more
Conditions
Head and Neck Cancer, Free Tissue Transfer
Interventions
Early Feeding
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Solid Tumors
Interventions
BMS-986484, Nivolumab, Oxaliplatin, Capecitabine, Fluorouracil, Calcium folinate
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • Grand Rapids, Michigan + 2 more
Conditions
Thyroid Nodule
Interventions
Mygen V-1000 RF system
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 90 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
New York, New York
Conditions
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Tongue Cancer
Interventions
carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil, hydroxyurea, therapeutic conventional surgery, radiation therapy, hyperfractionated radiation therapy, laboratory biomarker analysis
Drug · Procedure · Radiation + 1 more
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy

NCT05579782
Conditions
Postoperative Hypoparathyroidism, Thyroid Disease, Thyroid Neoplasms, Thyroid Cancer
Interventions
NIRAF Detection Technology
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction, Gastroesophageal Cancer, Squamous Cell Carcinoma, Gastric Adenocarcinoma
Interventions
DKN-01 150 mg, Paclitaxel, Pembrolizumab, DKN-01 300 mg
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more
Completed Phase 1Phase 2 Interventional Results available

Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma

NCT01195922
Conditions
Mouth Neoplasms, Head and Neck Neoplasms, Tongue Neoplasms, Carcinoma, Squamous Cell
Interventions
Sirolimus
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal
Interventions
INCB106385, INCMGA00012
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
West Hollywood, California • Baltimore, Maryland • Boston, Massachusetts + 5 more
Conditions
Mucositis, Head and Neck Cancer
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Sinonasal Squamous Cell Carcinoma AJCC v7
Interventions
Berzosertib, Cisplatin, Computed Tomography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
19
States / cities
Duarte, California • Sacramento, California • New Haven, Connecticut + 13 more
Conditions
Advanced Cancers
Interventions
Atorvastatin, Fish Oil Supplement, Placebo
Drug · Dietary Supplement · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Solid Tumors, Esophageal Cancer, Non-Small Cell Lung Cancer
Interventions
M1231
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Conditions
Ovarian Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer, Gastrointestinal Cancer, Triple Negative Breast Cancer, Ovarian Carcinoma
Interventions
TJ004309
Drug
Lead sponsor
I-Mab Biopharma US Limited
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Tucson, Arizona • Whittier, California • Newark, Delaware + 12 more
Conditions
Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
Interventions
TAK-500, Pembrolizumab, Tocilizumab, Dexamethasone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
MAGE-A3, HPV-16 vaccine
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Thyroid Neoplasms
Interventions
AG013736
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
9
States / cities
Santa Monica, California • Aurora, Colorado • Denver, Colorado + 5 more
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Nemvaleukin Alfa, Pembrolizumab
Drug
Lead sponsor
Mural Oncology, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Miami, Florida • Atlanta, Georgia • Minneapolis, Minnesota + 3 more
Conditions
Solid Tumor, Thyroid Cancer
Interventions
Capecitabine (Xeloda), DTIC-Dome (Dacarbazine), Gleevec (Imatinib Mesylate)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Houston, Texas
Conditions
Oropharyngeal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Houston, Texas